Viral-Specific T Lymphocytes for Treatment of Viral Infections in Primary Immunodeficiency
Year: 2015
Type: article
Abstract: Adoptive immunotherapy using virus-specific cytotoxic T-lymphocyte (VSTs) products has been successful in restoring antiviral immunity after hematopoietic stem cell transplantation (HSCT), and has been used to treat patients with primary immunodeficiency (PIDD). They may also be an invaluable salvage therapy for refractory viral infections prior to HSCT. VST can be produced from virus-exposed donors in as little as 10-14 days, and new protocols allow VST production from virus-naïve donors in 4-5 weeks.
Institutions: Children's National, Children's Hospital of Philadelphia
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W2323276777